Active clinical trials for laryngeal cancer with immune checkpoint inhibitors (ICIs) that are no longer recruiting [26]
| Trial identifier | Number of cancer patients | Intervention/Treatment regimen | Setting | Primary outcome(s) | Secondary outcome(s) |
|---|---|---|---|---|---|
| NCT04943445 | 43 laryngeals | Pembrolizumab-based therapy | Neoadjuvant (organ preservation) | Two-year laryngectomy-free survival | Two-year larynx dysfunction-free survival (alive without local recurrence or laryngoesophageal dysfunction) |
| NCT04030455 | 27 laryngeals | Cisplatin, docetaxel, pembrolizumab | Neoadjuvant | Disease control rate, pathological complete response rate | Incidence of adverse events, laryngeal preservation rate, relapse-free survival, overall survival, patient-reported quality of life |
| NCT04590963 | 370 head and neck (laryngeal unspecified) | Monalizumab, cetuximab | Recurrent/Metastatic | Overall survival in HPV-unrelated analysis set | Overall survival in full analysis set, progression-free survival, duration of response |
| NCT02586207 | 59 head and neck (laryngeal unspecified) | Pembrolizumab + chemoradiotherapy (CRT) | Neoadjuvant | Safety & tolerability | Efficacy, response rate |
| NCT03082534 | 78 head and neck (laryngeal unspecified) | Pembrolizumab + cetuximab | Recurrent/Metastatic | Clinical efficacy | Progression-free survival, overall survival, duration of response |
| NCT04576091 | 7 head and neck (laryngeal unspecified) | Pembrolizumab + radiation + BAY 1895344 (elimusertib) | Recurrent | Safety & tolerability | Incidence of adverse events, locoregional control, progression-free survival, overall response rate, 1-year overall survival, quality of life |
| NCT03370276 | 95 head and neck (laryngeal unspecified) | Cetuximab + nivolumab | Recurrent/Metastatic | Phase I: maximum tolerated dose, Phase II: overall survival | Overall response rate, progression-free survival, treatment-related adverse events |
| NCT03468218 | 36 head and neck (laryngeal unspecified) | Pembrolizumab + cabozantinib | Recurrent/Metastatic | Overall response rate | Progression-free survival |